Analytical Data
-
Gene name
IL-7
- Application
-
Biological Activity
1.The ED50 is <0>2.0 × 106 units/mg. 2.Measured in a cell proliferation assay using PHA-activated human peripheral blood lymphocytes (PBL). The ED50 for this effect is 0.02-0.08 ng/mL. 3.Measured in a cell proliferation assay using Jurkat cells. The ED50 for this effect is <0.5 ng/mL. Measured in a cell proliferation assay using Jurkat cells. The ED50 for this effect is 0.4102 ng/mL, corresponding to a specific activity is 2.438×106 units/mg.
-
Alternative Names
rHuIL-7; LP-1; pre-B cell factor
-
Species
Human
-
Source
E. coli
-
Tag
Tag Free
-
Purity
Greater than 95% as determined by reducing SDS-PAGE. as determined by SDS-PAGE.
-
Uniprot
P13232
-
Expression Region
D26-H177
-
Protein Length
Full Length of Isoform-1 Mature Protein
-
Molecular Weight
17-20 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Interleukin-7 (IL-7) is a crucial cytokine involved in the development, survival, and maintenance of T and B lymphocytes, playing a vital role in the immune system. Research on recombinant IL-7 protein has gained significant attention due to its potential therapeutic applications in immunodeficiency disorders, such as HIV/AIDS, and in enhancing anti-tumor immunity in cancer treatments. In the context of HIV, IL-7 can stimulate the proliferation of T-cells, potentially restoring immune function in infected individuals. Moreover, studies suggest that IL-7 may aid in expanding T-cell populations, which is essential for effective vaccine responses and for improving overall immune surveillance against tumors. The recombinant form of IL-7 can be produced using various expression systems, allowing for large-scale production and facilitating its use in clinical settings. Additionally, ongoing research is investigating the safety, dosage, and efficacy of IL-7 in combination therapies for both immunotherapy and regenerative medicine. Understanding the mechanisms by which IL-7 regulates lymphocyte homeostasis and function will not only enhance our knowledge of immune system dynamics but also pave the way for innovative strategies to harness its properties for therapeutic benefit.
